Regardless of strong points that this study was performed in quite homogenous group of patients, that is, HER2 positive MBC breast cancer patients who received TP as the first line therapy and that all the test was performed prospectively with the help of the independent pathologist, it has several limitations. This evidence concerns the gene ERBB2 and breast carcinoma.